Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that …
Biotechnology
US, Palo Alto [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Kodiak Sciences Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2019 | -2.7700 | -1.190 | 0 | 16 | -41 | -62 | -35 | 0 | -26 | 0 | 7 | 0 |
| 2020 | -1.2300 | -2.354 | 0 | 17 | -46 | -123 | -46 | 0 | -50 | 0 | 11 | 0 |
| 2023 | -6.3900 | -4.596 | 0 | 0 | -333 | -239 | -322 | 0 | -352 | 0 | 73 | 0 |
| 2024 | - | -3.394 | - | 62 | - | -180 | - | 0 | - | 0 | - | 0 |
| 2025 | - | -3.841 | - | 0.60 | - | -193 | - | 0 | - | 0 | - | 0 |
| 2026 | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F51/td> | - | 2.F51 | - | 2.F51 |
| 2027 | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F61/td> | - | 1.F61 | - | 1.F61 |
| 2028 | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F71/td> | - | 0.F71 | - | 0.F71 |